How to Help Your Patients Find Gemtesa in Stock: A Provider's Guide

You've prescribed Gemtesa for a patient with overactive bladder. A week later, they call back: their pharmacy doesn't have it, their insurance denied it, or they can't afford it at the cash price. This is a frustratingly common scenario — and one you can proactively address.

This guide gives you practical tools and talking points to help your patients successfully access Gemtesa (vibegron) in 2026.

Step 1: Set Access Expectations at the Point of Prescribing

When you prescribe Gemtesa, set your patients up for success before they leave your office. A few quick talking points:

Tell them the drug is brand-only and that not every pharmacy stocks it. Recommend they call ahead before going to the pharmacy.

Let them know insurance may require prior authorization — and that your office will help submit it proactively.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

For patients who want help locating a pharmacy: medfinder calls pharmacies near them and texts which ones have their medication in stock.

Step 2: Submit Prior Authorization Proactively

Don't wait for the pharmacy to reject the claim. For most commercial and Medicare Part D plans, a PA will be required. Submit it on the day you prescribe. When building your PA request, include:

Documented OAB diagnosis and symptom severity (urgency episodes/day, incontinence frequency, functional impact)

Prior anticholinergic trials with documented failure, inadequate response, or intolerance (dry mouth, constipation, cognitive effects)

Clinical rationale for Gemtesa specifically — such as: concurrent CYP2D6-sensitive medications making mirabegron less safe, hypertension concerns, geriatric cognitive safety, or prior mirabegron trial failure

For men with BPH: include documentation of current pharmacological BPH therapy and OAB symptom burden to support the expanded 2024 indication

Step 3: Help Patients Navigate Pharmacy Access

When a patient reports the pharmacy doesn't have Gemtesa in stock, these are the most effective options:

Electronic prescription transfer. Ask your office to send the e-prescription to a pharmacy that has confirmed stock. Patients or your staff can call larger chain pharmacies (CVS, Walgreens, hospital pharmacy) to confirm inventory.

Mail-order pharmacy referral. Write a 90-day quantity prescription to send to a mail-order pharmacy. These services maintain reliable Gemtesa inventory and offer cost savings.

medfinder referral. medfinder.com calls pharmacies near the patient to find who has their medication in stock, and texts results. This is particularly helpful for patients who cannot easily make multiple phone calls.

Step 4: Guide Patients Through Savings Programs

Having a brief savings resource guide at your front desk or in your patient instructions can dramatically reduce drop-off after prescribing:

Gemtesa Simple Savings Program (Sumitomo Pharma): Commercially insured patients with coverage: as little as $10/30-day or $0/90-day. Without coverage: $95/month. NOT available to Medicare/Medicaid patients. Text GEMTESA to 436872 or visit gemtesa.com/savings-and-pricing.

Patient Assistance Program (Sumitomo Pharma): For eligible uninsured or underinsured patients — medication provided at no charge. Call 1-833-876-8268 for eligibility information.

Medicare Extra Help: Eligible low-income Medicare patients may qualify for extra help subsidizing prescription costs — brand-name drugs max out at ~$12.65/refill.

Step 5: Have a Fallback Plan

If a patient's access is persistently blocked, having a therapeutic alternative ready prevents gaps in OAB care. Generic mirabegron ER is the most pharmacologically similar alternative. For patients where beta-3 agonists are not an option, once-daily solifenacin or tolterodine extended-release offer effective alternatives with generic pricing. See our full provider overview at Gemtesa: What Providers Need to Know in 2026.